49 Investor presentation First nine months of 2021 PIONEER programme with oral se PIONEER Baseline 1 8.0% -0.1 2 8.1% 3 8.3% 4 8.0% Change in HbA 1c (%) Baseline -0.8 * -1.3 * -1.5 * 88 kg -0.9 -1.4 * 92kg -0.5 -0.8 -1.1 * -1.4 * 91 kg -1.3 94 kg Change in weight (kg) -1.7 -1.5 -2.5 * -4.1 * -1.2 * -0.7 -2.2 * -3.3 * -3.8 -4.2 -4.7 oral semaglutide 3 mg oral semaglutide 7 mg oral semaglutide 14 mg pla Note: PIONEER 9 and PIONEER 10 were Japanese studies and PIONEER 6 was a CV safety study. * Statistically significant based on th PIONEER 2: QD oral sema vs empagliflozin 25 mg in people with T2D; PIONEER 3: QD oral sema vs sitagliptin 100 mg in people with with T2D and moderate renal impairment; PIONEER 7: QD oral sema using a flexible dose adjustment based on clinical evaluation v treated with insulin ER: Extended-release; QW: once weekly; QD: once daily; oral sema: oral semaglutide; T2D: type 2 diabetes, OAD
Download PDF file